title: Dynamics of hydroxyoctadecadienoic acid in epilepsy patients treated with valproic acid.
abstract: BACKGROUND
  The effects of valproic acid (VPA) on oxidative stress are controversial due to differences in experimental conditions. Recently, total hydroxyoctadecadienoic acid (tHODE), derived from linoleic acid, was proposed as a potent biomarker to evaluate oxidative stress.
  
  
  METHODS
  The subjects consisted of 10 new-onset epilepsy patients treated with VPA. We measured plasma tHODE consecutively for 1 year to evaluate the degree of oxidative stress and then compared plasma tHODE at the beginning and the end of experiments with the peak level. Ten age-matched healthy subjects were recruited as a control group and their plasma tHODE was compared to the initial plasma tHODE of the epilepsy group. Measurements were done using liquid chromatography-tandem mass spectrometry.
  
  
  RESULTS
  Mean initial plasma tHODE in the epilepsy group was 165.2 ± 76.8 nmol/L, which was not significantly different from that of the control group (199.3 ± 62.5 nmol/L). In five epilepsy patients, plasma tHODE increased above the pathological level in 6 months, but returned to normal within 1 year. In the whole group, the difference plasma tHODE between peak, at the beginning and 1 year later, was significant.
  
  
  CONCLUSIONS
  Oxidative stress generated by VPA increased temporarily, but decreased to normal after 1 year. it is reasonable to be concerned about the effects of oxidative stress, especially at the start of VPA treatment.
authors.affiliation: Department of Pediatrics, Seikeikai Hospital, Osaka, Japan.|Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Osaka, Japan.
authors.forename: Kohji
authors.initials: K
authors.lastname: Azumagawa
authors.affiliation: Department of Pediatrics, Seikeikai Hospital, Osaka, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Mino
authors.affiliation: Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Osaka, Japan.
authors.forename: Noriko
authors.initials: N
authors.lastname: Ishida
authors.affiliation: Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Osaka, Japan.
authors.forename: Mototada
authors.initials: M
authors.lastname: Shichiri
authors.affiliation: Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Osaka, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Shigeri
authors.affiliation: Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Osaka, Japan.
authors.forename: Yasukazu
authors.initials: Y
authors.lastname: Yoshida
authors.affiliation: Department of Pediatrics, Osaka Medical College, Osaka, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamai
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy; D005231:Fatty Acids, Unsaturated / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D018384:Oxidative Stress; D012189:Retrospective Studies; D014635:Valproic Acid / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D005231:Fatty Acids, Unsaturated; C495366:hydroxyoctadecadienoic acid; D014635:Valproic Acid
keywords: oxidative stress; pediatric epilepsy; total hydroxyoctadecadienoic acid; valproic acid